Glaucoma, a neurodegenerative disorder is characterized by damage of ganglion cells of retina and also its axons. The manner of progression of disease and retinal ganglion cells death in glaucoma still remains unknown and hence many mechanisms are put forward to understand the disease. Clinical developments have suggested that in every single patient decreasing intraocular pressure (IOP) is not the solution to prevent glaucoma which suggests on the fact that there are other risk factors affecting the disease. The demand for substitute unconventional treatments gives rise to the need to understand the biologically based tactics (bio-tactics) for stopping the progression of disease. Pragmatic findings of past years have supported novelty of inventive molecules with hallmark of neuroprotection in gene therapy. On the other hand, transformation of the latest drugs to clinic has not been of much fruitful substantially for the reason that it lacked dependability while measuring in vivo retinal injury. This as a consequence thwarted the high quality healing possibility of neuroprotectants whether administered single-handedly or given complimentary with other IOP reducing agents. Advancement in research is crucial to grasp the underlying mechanisms concerned with glaucoma and apply it in clinical field to develop neuroprotective agents. In this context, the present review is to bring forth an update on up to date progress in the domain of neuroprotection of retinal ganglion cells for treating glaucoma.

中文翻译：

---

视网膜神经节细胞在青光眼治疗中的神经保护生物策略。

青光眼是一种神经退行性疾病，其特征在于视网膜神经节细胞及其轴突受损。青光眼的疾病进展方式和视网膜神经节细胞死亡的方式仍然未知，因此提出了许多机制来理解该疾病。临床发展表明，在每位患者中降低眼内压（IOP）并不是预防青光眼的解决方案，这表明存在影响疾病的其他危险因素这一事实。对替代性非常规疗法的需求引起了对理解基于生物学的策略（生物策略）以停止疾病发展的需求。过去几年的务实发现支持了具有基因保护作用的基因治疗发明分子的新颖性。另一方面，由于在测量体内视网膜损伤时缺乏可靠性，因此最新药物向临床的转化并没有取得实质性的成果。结果，无论是单手施用还是与其他IOP降低剂配合使用，都阻止了神经保护剂的高质量治愈可能性。研究进展对于掌握与青光眼有关的潜在机制并将其应用于临床领域以开发神经保护剂至关重要。在这种情况下，本综述将对用于治疗青光眼的视网膜神经节细胞的神经保护领域的最新进展进行更新。结果，无论是单手施用还是与其他IOP降低剂配合使用，都阻止了神经保护剂的高质量治愈可能性。研究进展对于掌握与青光眼有关的潜在机制并将其应用于临床领域以开发神经保护剂至关重要。在这种情况下，本综述将提出用于治疗青光眼的视网膜神经节细胞的神经保护领域的最新进展。结果，无论是单手施用还是与其他IOP降低剂配合使用，都阻止了神经保护剂的高质量治愈可能性。研究进展对于掌握与青光眼有关的潜在机制并将其应用于临床领域以开发神经保护剂至关重要。在这种情况下，本综述将对用于治疗青光眼的视网膜神经节细胞的神经保护领域的最新进展进行更新。